<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006302.pub2" GROUP_ID="UPPERGI" ID="664105021509504750" MERGED_FROM="" MODIFIED="2010-09-21 21:27:45 +0200" MODIFIED_BY="Karin Dearness" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.2">
<COVER_SHEET MODIFIED="2010-09-21 21:27:45 +0200" MODIFIED_BY="Karin Dearness">
<TITLE>Pancreatic enzymes for chronic pancreatitis</TITLE>
<CONTACT MODIFIED="2010-09-21 21:27:45 +0200" MODIFIED_BY="Karin Dearness"><PERSON ID="DAB6EC5282E26AA2001A7553BF8EF949" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Samir</FIRST_NAME><LAST_NAME>Malhotra</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>samirmalhotra345@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pharmacology</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><ZIP>160012</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 172 272 1293</PHONE_1><FAX_1>+91 172 274 4401</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 21:27:45 +0200" MODIFIED_BY="Karin Dearness"><PERSON ID="DABBCE4282E26AA2001A7553B0565C46" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nusrat</FIRST_NAME><LAST_NAME>Shafiq</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>nusrat_shafiq@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pharmacology</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><ZIP>160012</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 (172) 2747585 ext 5240</PHONE_1><FAX_1>+91 (172) 2744401</FAX_1></ADDRESS></PERSON><PERSON ID="081ACE8A82E26AA200831C19DF3AC7CE" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Surinder</FIRST_NAME><LAST_NAME>Rana</LAST_NAME><POSITION>Senior Resident</POSITION><EMAIL_1>drsurinderrana@yahoo.co.in</EMAIL_1><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><ZIP>160012</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 172 2756243</PHONE_1></ADDRESS></PERSON><PERSON ID="DAB859BD82E26AA2001A755365CC37F4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Deepak</FIRST_NAME><LAST_NAME>Bhasin</LAST_NAME><EMAIL_1>deepakkbhasin@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 172 2747585 ext 6243</PHONE_1><FAX_1>+91 172 2744401</FAX_1></ADDRESS></PERSON><PERSON ID="DAB9D9A682E26AA2001A75535E7F0EA4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Promila</FIRST_NAME><LAST_NAME>Pandhi</LAST_NAME><EMAIL_1>ppandhi17@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pharmacology</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 (172) 2747585 ext 5241</PHONE_1><FAX_1>+91 (172) 2744401</FAX_1></ADDRESS></PERSON><PERSON ID="78EBA94D82E26AA200CE0284D6B796AE" ROLE="AUTHOR"><FIRST_NAME>Puja</FIRST_NAME><LAST_NAME>Srivastava</LAST_NAME><POSITION>Junior Resident</POSITION><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><COUNTRY CODE="IN">India</COUNTRY></ADDRESS></PERSON><PERSON ID="1801069E82E26AA201A9DC55D54A40AA" ROLE="AUTHOR"><FIRST_NAME>Surjit</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Sehmby</LAST_NAME><POSITION>c/o Dr Samir Malhotra</POSITION><EMAIL_1>samirmalhotra345@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pharmacology</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><ZIP>160012</ZIP><COUNTRY CODE="IN">India</COUNTRY></ADDRESS></PERSON><PERSON ID="081ACA9282E26AA200831C192D35A8B9" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Raj</FIRST_NAME><LAST_NAME>Kumar</LAST_NAME><POSITION>Librarian</POSITION><EMAIL_1>pgilibrary@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Dr. Tulsidas Library</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><ADDRESS_1>Sector 12</ADDRESS_1><CITY>Chandigarh</CITY><ZIP>160012</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 172 2755757</PHONE_1></ADDRESS></PERSON><PERSON ID="DAB6EC5282E26AA2001A7553BF8EF949" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Samir</FIRST_NAME><LAST_NAME>Malhotra</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>samirmalhotra345@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pharmacology</DEPARTMENT><ORGANISATION>Postgraduate Institute of Medical Education and Research</ORGANISATION><CITY>Chandigarh</CITY><ZIP>160012</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 172 272 1293</PHONE_1><FAX_1>+91 172 274 4401</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-09-21 21:27:45 +0200" MODIFIED_BY="Karin Dearness">
<UP_TO_DATE>
<DATE DAY="17" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="2" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 21:27:45 +0200" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 21:27:45 +0200" MODIFIED_BY="Karin Dearness"><DATE DAY="21" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW>
<HISTORY MODIFIED="2009-07-29 08:46:39 -0400" MODIFIED_BY="Jenny Bellorini">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-16 15:03:35 -0500" MODIFIED_BY="Karin L Dearness">
<DATE DAY="12" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Dept of Pharmacology, PGIMER, Chandigarh</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-11 09:34:34 -0400" MODIFIED_BY="Karin L Dearness">
<SUMMARY MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<TITLE MODIFIED="2008-12-12 15:56:56 -0500" MODIFIED_BY="Karin L Dearness">Pancreatic enzymes for chronic pancreatitis</TITLE>
<SUMMARY_BODY MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<P>Chronic pancreatitis is a condition afflicting nearly 0.04% to 5% of the population worldwide. The disease presents as recurrent episodes of abdominal pain, fatty stools and weight loss, or may be asymptomatic. Patients may develop complications over a variable period of time. Medical treatment often involves prescription of pancreatic enzyme preparations for these patients. This practice is based on studies which have shown the benefit of pancreatic enzymes on various outcomes such as abdominal pain, weight loss, analgesic use, fatty stools and quality of life. However, a collective conclusion about the role of pancreatic enzymes in chronic pancreatitis patients needs to be established from these studies. This systematic review aimed to collect all published and unpublished data on this subject in order to evaluate whether pancreatic enzymes have any benefit on various parameters in chronic pancreatitis, to compare different types of enzyme preparations and to evaluate whether different dosage schedules have any influence on the various outcomes. We included 10 studies in the review. These studies had enrolled small numbers of patients. Though individual studies showed benefit of varying degrees on the parameters mentioned above, we could not pool the results of these studies. With the evidence available so far, no definitive conclusion can be drawn for the benefit of pancreatic enzymes in patients with chronic pancreatitis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-11 09:32:01 -0400" MODIFIED_BY="Karin L Dearness">
<ABS_BACKGROUND MODIFIED="2009-06-13 02:05:56 -0400" MODIFIED_BY="[Empty name]">
<P>The efficacy of pancreatic enzymes in reducing pain and improving steatorrhoea is debatable and the evidence base for their utility needs to be determined.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<P>To evaluate the efficacy of pancreatic enzymes in patients with chronic pancreatitis. The specific objectives were to compare the following: 1) pancreatic enzyme versus placebo; 2) different pancreatic enzyme preparations and 3) different dosage schedules of the enzyme preparations. We evaluated the following outcomes: change in frequency of abdominal pain, duration of pain episodes, intensity of pain, weight loss, steatorrhoea, faecal fat and quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-11 09:32:01 -0400" MODIFIED_BY="Karin L Dearness">
<P>We devised a search strategy to detect all published and unpublished literature and the search included CENTRAL (<I>The Cochrane Library</I> 2009, issue 1), MEDLINE (1965 to February 2009) and EMBASE (1974 to Feburary 2009). We handsearched reference lists and published abstracts from conference proceedings to identify further relevant trials. The date of the last search was April 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised controlled trials with or without blinding. We included abstracts or unpublished data if sufficient information was available.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<P>Two authors independently extracted and pooled the data pertinent to study outcomes. We combined continuous data using standardised mean difference (SMD) with 95% confidence interval (CI) and calculated the odds ratio (OR) for dichotomous data (95% CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<P>Ten trials, involving 361 participants, satisfied the inclusion criteria. All the trials were randomised; two had a parallel design while the remainder had a cross-over design. Although some individual studies reported a beneficial effect of pancreatic enzyme over placebo in improving pain, incidence of steatorrhoea and analgesic consumption, the results of the studies could not be pooled for these outcomes. With the use of pancreatic enzymes, we observed a non-significant benefit for weight loss (kg) (SMD 0.06; 95% CI -0.23 to 0.34); a significant reduction in faecal fat (g/day) (SMD -1.03; 95% CI -1.60 to -0.46) and non-significant difference in subjects' Clinical Global Impression of Disease Symptom Scale (SMD -0.63; 95% CI -1.41 to 0.14). We found no significant benefit in reducing faecal fat with any particular schedule of enzyme preparation or type of enzyme.</P>
<P>Another small study did not show any significant benefit of timing the administration of enzyme preparations in relation to meals on faecal fat.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<P>The role of pancreatic enzymes for abdominal pain, weight loss, steatorrhoea, analgesic use and quality of life in patients with chronic pancreatitis remains equivocal. Good quality, adequately powered studies are much warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-11 09:34:34 -0400" MODIFIED_BY="Karin L Dearness">
<BACKGROUND MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<CONDITION MODIFIED="2009-07-31 08:57:22 -0400" MODIFIED_BY="Karin L Dearness">
<P>Chronic pancreatitis is known to afflict approximately 0.04% to 5% of the population worldwide (<LINK REF="REF-Owyang-1991" TYPE="REFERENCE">Owyang 1991</LINK>). A regional variation has been noted in the prevalence of the condition with a prevalence of 27.4 per 100,000 reported in Scandinavia and approximately one per 830 in the orient and India (<LINK REF="REF-Copenhagen-1981" TYPE="REFERENCE">Copenhagen 1981</LINK>). The condition is associated with mortality rate that approaches 50% within 20 to 25 years (<LINK REF="REF-Steer-1995" TYPE="REFERENCE">Steer 1995</LINK>). Approximately 15% to 20% of patients die of complications associated with exacerbation of symptoms, which occurs from time to time, and most of the remaining deaths are due to factors such as trauma, malnutrition, infection or tobacco abuse, which are frequently present in patients with alcoholic pancreatitis (<LINK REF="REF-AGA-1998" TYPE="REFERENCE">AGA 1998</LINK>). Chronic pancreatitis is associated with diverse aetiologies such as alcohol intake, obstructive lesions of the pancreatic duct, hyperparathyroidism and autoimmunity (<LINK REF="REF-Bhadada-2007" TYPE="REFERENCE">Bhadada 2007</LINK>; <LINK REF="REF-Bhasin-2006" TYPE="REFERENCE">Bhasin 2006</LINK>; <LINK REF="REF-Greenberger-2005" TYPE="REFERENCE">Greenberger 2005</LINK>). The pathophysiology of the disease is multifactorial and includes environmental, nutritional, chemical and genetic abnormalities (<LINK REF="REF-Behrman-2007" TYPE="REFERENCE">Behrman 2007</LINK>). Approximately 20% to 30% of cases may be idiopathic (<LINK REF="REF-Layer-1994" TYPE="REFERENCE">Layer 1994</LINK>) and in some heredity may play a role (<LINK REF="REF-Etemad-2001" TYPE="REFERENCE">Etemad 2001</LINK>). With the advent of new laboratory and technological advances, it has been possible to reveal the aetiology in 79% to 80% of patients who would previously have been labelled as idiopathic pancreatitis (<LINK REF="REF-Lee-2007" TYPE="REFERENCE">Lee 2007</LINK>). Additionally, with the identification of genetic mutations, a large number of these cases would no longer be classified as idiopathic. After two initial reports of an increased incidence of cystic fibrosis transmembrance conductance regulator (CFTR) gene mutation in patients with chronic pancreatitis, mutations in other genes such as serine protease inhibitor (SPINK 1) and the protease serine 1 (PRSS1) have been shown to be associated with chronic pancreatitis (<LINK REF="REF-Cohn-1998" TYPE="REFERENCE">Cohn 1998</LINK>; <LINK REF="REF-Kiraly-2007" TYPE="REFERENCE">Kiraly 2007</LINK>; <LINK REF="REF-Whitcomb-1996" TYPE="REFERENCE">Whitcomb 1996</LINK>; <LINK REF="REF-Witt-2005" TYPE="REFERENCE">Witt 2005</LINK>).</P>
<P>After a subclinical phase of variable duration, exocrine or endocrine insufficiency (or both) may appear. In most cases, both exocrine and endocrine functions are lost (<LINK REF="REF-Steer-1995" TYPE="REFERENCE">Steer 1995</LINK>). Exocrine insufficiency seen in chronic pancreatitis manifests as maldigestion and malnutrition. A retrospective study has estimated a 30% to 40% incidence of exocrine pancreatic insufficiency in patients with chronic pancreatitis (<LINK REF="REF-Kalthoff-1984" TYPE="REFERENCE">Kalthoff 1984</LINK>). It may develop soon after the onset of chronic pancreatitis or may take 25 years to evolve (<LINK REF="REF-Layer-1994" TYPE="REFERENCE">Layer 1994</LINK>). The exocrine tissue may be destroyed because of long-standing inflammation and fibrosis of the gland. Inadequate delivery of bicarbonate to the duodenum and secondary inactivation of the enzyme and bile acids by gastric acids further aggravate maldigestion. Other factors, such as poor oral intake, continuing intake of alcohol, gastric dysmotility and mechanical outlet obstruction, may all aggravate the maldigestion (<LINK REF="REF-Bruno-1995" TYPE="REFERENCE">Bruno 1995</LINK>). In patients with extensive damage to the pancreas (&lt; 10% of the exocrine function remaining), steatorrhoea (faecal loss of fat) and azotorrhea (faecal loss of proteins) may occur (<LINK REF="REF-Greenberger-2005" TYPE="REFERENCE">Greenberger 2005</LINK>).</P>
<P>Pain is a common presenting feature (<LINK REF="REF-Steer-1995" TYPE="REFERENCE">Steer 1995</LINK>). It may be continuous or intermittent. In 10% to 20% of patients, pain may be absent. In some patients fibrosis and scarring of pancreatic tissue may ultimately lead to pancreatic burnout and spontaneous relief of pain. The issue of pancreatic burnout, however, is debatable. It is suggested that relief of pain in these cases may be due to patients getting used to pain or avoiding factors precipitating pain. Several mechanisms, such as elevated intraductal pressure, neural inflammation, neurohormonal changes, gastroparesis and increase in cholecystokinin levels, have all been proposed as the likely cause for the pain of pancreatitis (<LINK REF="REF-Ammann-1999" TYPE="REFERENCE">Ammann 1999</LINK>). Pain may also be due to other causes, such as pancreatic malabsorption, or steatorrhoea, and could also be non-visceral (<LINK REF="REF-Ammann-1999" TYPE="REFERENCE">Ammann 1999</LINK>). Biliary and colonic strictures (<LINK REF="REF-Frey-1990" TYPE="REFERENCE">Frey 1990</LINK>) and the development of malignancy (<LINK REF="REF-Hsu-2005" TYPE="REFERENCE">Hsu 2005</LINK> ) may also lead to pancreatic pain.</P>
<P>Patients may also present with diabetes, jaundice or malabsorption. The morphologic changes of chronic pancreatitis include varying degrees of oedema, acute inflammation and necrosis, superimposed on a background of chronic changes that include fibrosis, inflammation and loss of exocrine tissue. Ductal elements may be dilated, and intraductal protein plugs, which may be calcified, can be seen (<LINK REF="REF-Steer-1995" TYPE="REFERENCE">Steer 1995</LINK>). The condition is characterised by a progressive loss of pancreatic parenchymal tissue (<LINK REF="REF-Kloppel-1992" TYPE="REFERENCE">Kloppel 1992</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>Therapy for patients with chronic pancreatitis is directed towards three major problems - pain, malabsorption and complications of pancreatitis, such as pseudocysts, fistulae and biliary obstruction. Additionally, complications such as diabetes need to be managed as they arise.</P>
<P>Though pancreatic enzyme supplements are the mainstay of treatment for exocrine pancreatic insufficiency in chronic pancreatitis, other measures, like substitution of part of their fat intake by medium chain triglycerides, may act as adjuvant treatments (<LINK REF="REF-Steer-1995" TYPE="REFERENCE">Steer 1995</LINK>).</P>
<P>Non-invasive approaches for management of pain include advising abstinence from alcohol or other causative agents and administering analgesic medications. Minimally invasive procedures such as nerve blocks and endoscopic decompression, or surgical techniques like ductal decompression or side to side pancreaticojejunostomy, may prove helpful in ameliorating pain. In some cases of intractable pain, partial surgical resection of the gland, such as pylorus preserving pancreatectomy, duodenum preserving head resection or tail resection, Frey procedure, side to side pancreaticojejunostomy and total pancreatectomy with or without islet cell transplantation, may be undertaken (<LINK REF="REF-AGA-1998" TYPE="REFERENCE">AGA 1998</LINK>; <LINK REF="REF-Schnelldorfer-2008" TYPE="REFERENCE">Schnelldorfer 2008</LINK>). However, these surgical procedures may be associated with loss of exocrine and endocrine functions as well as complications related to the procedure.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>Diarrhoea and steatorrhoea show improvement with pancreatic enzyme replacement. Lipase is the most important component of pancreatic enzyme supplements. The enzyme replacement may differ in the formulation (non-enteric coated or enteric coated microsphere preparations) or timing of administration (with food, before or after food) (<LINK REF="REF-Bruno-1995" TYPE="REFERENCE">Bruno 1995</LINK>). Enteric coated preparations were developed in an attempt to protect pancreatin from acidic inactivation by preventing liberation of enzymes at acidic pH of the stomach. In the small intestine, where the pH is likely to rise above a particular pH threshold, the enteric coat dissolves, releasing the enzymes. Various enteric coated microsphere preparations show marked differences in physical characteristics, such as total enzyme content, particle size, lipase/protease ratio, pH threshold of dissolution of the enteric coating, and the rate of enzyme release. There is a need to evaluate the differential efficacy of these enzyme preparations (<LINK REF="REF-FDA-2004" TYPE="REFERENCE">FDA 2004</LINK>; <LINK REF="REF-Greenberger-1999" TYPE="REFERENCE">Greenberger 1999</LINK>). Additionally, the dosing schedule of the enzymes may also influence the clinical outcome and needs to be evaluated in a systematic review (<LINK REF="REF-Dominguez-2005" TYPE="REFERENCE">Dominguez 2005</LINK>).</P>
<P>Normally, the release of cholecystokinin from specific intestinal cells is regulated by a cholecystokinin-releasing peptide in the proximal small intestine that is luminally active and trypsin-sensitive (<LINK REF="REF-Sandberg-1989" TYPE="REFERENCE">Sandberg 1989</LINK>). Pancreatic enzymes are proposed to suppress the release of cholecystokinin-releasing peptide by a negative feedback mechanism. Pancreatic enzymes may produce a beneficial effect on pain through this mechanism although other mechanisms such as reduction in steatorrhoea may be important. Pancreatic enzymes have been evaluated for their efficacy in relieving pain (<LINK REF="REF-Czack-2003" TYPE="REFERENCE">Czack 2003</LINK>; <LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>; <LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>; <LINK REF="REF-Slaff-1984" TYPE="REFERENCE">Slaff 1984</LINK>). The results of these studies are varied and an earlier meta-analysis (<LINK REF="REF-Brown-1997" TYPE="REFERENCE">Brown 1997</LINK>) concludes no benefit of pancreatic enzyme preparations over placebo in reducing pain in patients with chronic pancreatitis. The parameter evaluated in this meta-analysis was percentage of patients showing preference for enzymes over placebo. No evaluation of visual analogue scales of pain, analgesics used or frequency of episodes of pain was made and few studies have subsequently investigated the role of pancreatic enzymes in reducing pain either as their primary objective or a secondary objective.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>The review aims to highlight the comparative efficacy of various types of enzyme preparations in chronic pancreatitis. Additionally, it will also evaluate the role of pancreatic enzymes in reducing abdominal pain associated with chronic pancreatitis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>To evaluate the efficacy of pancreatic enzymes in patients with chronic pancreatitis.</P>
<P>Comparisons will be as follows.</P>
<OL>
<LI>Pancreatic enzyme versus placebo in changing the frequency of abdominal pain, duration of pain episodes, intensity of pain, weight loss, steatorrhoea, analgesic use and quality of life.</LI>
<LI>Different pancreatic enzyme preparations in changing the frequency of abdominal pain, duration of pain episodes, intensity of pain, weight loss, steatorrhoea, analgesic use and quality of life.</LI>
<LI>Different dosage schedules of enzyme preparations in changing the frequency of abdominal pain, duration of pain episodes, intensity of pain, weight loss, steatorrhoea, analgesic use and quality of life.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<SELECTION_CRITERIA MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<CRIT_STUDIES MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Randomised controlled trials, with or without blinding. We included abstracts or unpublished data if sufficient information on study design, characteristics of participants, interventions and outcomes was available and if full information, as well as final results, could be confirmed by contacting the first author.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>We excluded open, uncontrolled, observational studies from the meta-analysis.</P>
</SUBSECTION>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>We included studies that evaluated patients with chronic pancreatitis in the meta-analysis. The criteria for the diagnosis of chronic pancreatitis included in these studies were clinical grounds and the presence of:</P>
<OL>
<LI>grade II to IV changes in the main pancreatic duct and the branches of the main pancreatic duct at endoscopic retrograde cholangiopancreatography (ERCP) as per the Cambridge classification, or chronic pancreatitis diagnosed on magnetic resonance cholangiopancreatography (MRCP) OR parenchymal (gland atrophy, hyperechoic foci, hyperechoic stranding, cysts, lobularity)/ductal (narrowing, dilation, irregularity, calculi, side branch dilation, hyperechoic endoscopic walls) on endoscopic ultrasonography (EUS);</LI>
<LI>pancreatic calcifications on plain film or and on computed tomography (CT);</LI>
<LI>abnormalities at ultrasonography (US) scan; and</LI>
<LI>pancreatic insufficiency as diagnosed by one or more of the following: the secretin-cerulein test, positive Lundh test, the lipiodol test, faecal elastase less than 200 microgram/day or chymotrypsin less than 20 U/gram.</LI>
</OL>
<P>It should be noted that the diagnostic criteria for chronic pancreatitis have undergone several revisions since they were first outlined in 1963. Due to lack of consensus on the definition of chronic pancreatitis, clinical investigators have used various definitions for chronic pancreatitis (<LINK REF="REF-Etemad-2001" TYPE="REFERENCE">Etemad 2001</LINK>). 
<BR/>

</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>Orally administered pancreatic extract preparations (uncoated or enteric coated microspheres).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>Change in subjective pain scores and amount of faecal fat for evaluation of chronic pancreatic insufficiency.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<OL>
<LI>Change in frequency of abdominal pain</LI>
<LI>Change in duration of pain symptoms</LI>
<LI>Change in analgesic use</LI>
<LI>Change in weight loss</LI>
<LI>Change in incidence of steatorrhoea</LI>
<LI>Change in quality of life scores</LI>
</OL>
<P>Further, it was planned that the studies would be ordered by follow-up times to see if there was any time trend in the above mentioned outcomes, if sufficient data could be extracted.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<ELECTRONIC_SEARCHES MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>We conducted a search to identify all published and unpublished randomised controlled trials.</P>
<P>We identified trials by searching the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, issue 1), MEDLINE and EMBASE. We handsearched reference lists from trials selected by electronic searching to identify further relevant trials. We also handsearched published abstracts from conference proceedings from the United European Gastroenterology Week (published in <I>Gut</I>) and Digestive Disease Week (published in <I>Gastroenterology</I>).</P>
<P>We constructed the search strategy for this review by using a combination of MESH subject headings and text words relating to the use of pancreatic enzymes for the treatment of chronic pancreatitis.</P>
<P>To identify randomised controlled trials, we combined the search (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) with the Cochrane highly sensitive search strategy phases one, two and three as contained in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<P>The date of the last search was 1 April 1009.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>We also searched the following web resources:</P>
<UL>
<LI>
<A HREF="http://www.controlledtrials.com">http://www.controlledtrials.com</A>;</LI>
<LI>
<A HREF="http://www.cancer.gov/cancerinformation">http://www.cancer.gov/cancerinformation</A>;</LI>
<LI>
<A HREF="http://clinicaltrials.gov">http://clinicaltrials.gov</A>;</LI>
<LI>
<A HREF="http://www.eortc.be">http://www.eortc.be</A>;</LI>
<LI>
<A HREF="http://www.swog.org">http://www.swog.org</A>;</LI>
<LI>
<A HREF="http://www.ctg.queensu.ca">http://www.ctg.queensu.ca</A>; and</LI>
<LI>
<A HREF="http://www.CenterWatch.com/">http://www.CenterWatch.com/</A>.</LI>
</UL>
<P>In addition, we contacted members of the Cochrane UGPD Group and experts in the field and asked them to provide details of outstanding clinical trials and any relevant unpublished materials</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY_SELECTION MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>In order to select studies for further assessment, two independent authors scanned the title, abstract section and keywords of every record retrieved. Full articles or abstracts providing sufficient information were taken into account for further assessment if the information given suggested that the study satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>If there was any doubt regarding these criteria from the information given in the title and abstract, we retrieved the full article for clarification. If differences in opinion existed, we resolved these by discussion. If no clarification was provided, we consulted the review group editorial base. We extracted all the relevant data for the review.</P>
<P>Two authors independently extracted details of study population, interventions and outcomes using a standardised data extraction form. This form included at least the following items:</P>
<UL>
<LI>general information: title, authors, source, contact address, country, published/unpublished, language and year of publication, sponsor of trial;</LI>
<LI>trial characteristics: design, duration/follow up and quality assessment criteria as specified above;</LI>
<LI>patients: inclusion and exclusion criteria, sample size, baseline characteristics, similarity of groups at baseline, withdrawals and losses to follow up;</LI>
<LI>interventions: dose, route, duration of treatment, concomitant medications;</LI>
<LI>outcomes: number of pain episodes,visual analogue scores, median, mean, standard deviation, number of analgesics used, weight loss and faecal fat.</LI>
</UL>
<P>Additionally, we also presented weight loss and steatorrhoea as binary data and calculated odds ratios wherever possible.</P>
<P>We developed a template data extraction form and tested this in a pilot study. Two evaluators independently performed data extraction and data entry in duplicate. We resolved differences in data extraction by consensus with a third author, referring back to the original article. If data were missing in a published report, the review authors contacted the first author.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>Two authors independently assessed the risk of bias of the eligible studies unblinded, with disagreements resolved by a third author until consensus was obtained. We extracted data using an assessment form designed for the topic of this review (<I>Cochrane Handbook for Systematic Reviews of Interventions</I>). We considered the following criteria:</P>
<OL>
<LI>Was the allocation truly random?</LI>
<LI>Was the treatment allocation concealed?</LI>
<LI>Were the groups similar at baseline regarding the most important prognostic factors?</LI>
<LI>Were the number of withdrawals, drop-outs and losses to follow up in each group completely described?</LI>
<LI>Was the analysis done by intention-to-treat?</LI>
<LI>Were type and schedule of the follow up similar in the comparison group?</LI>
</OL>
<P>Answers to these questions were categorised as:</P>
<UL>
<LI>yes (a);</LI>
<LI>no (b);</LI>
<LI>unclear (c).</LI>
</UL>
<P>Based on these criteria, the studies were broadly subdivided into the following three categories of quality:</P>
<P>A - all of the criteria met: low risk of bias;<BR/>B - all criteria of question 1, 2 and 3 met; one or more of criteria 4 to 6 not met;<BR/>C - question 1 met, one or more of questions 2 to 6 not met;<BR/>D - unclear: insufficient information given (in these cases, the first author of the study was contacted).</P>
<P>We used this classification as the basis of a sensitivity analysis.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>For continuous data we calculated the standardised mean difference (SMD). For binary outcomes, we calculated the odds ratio (OR) and 95% confidence intervals (CIs) as relevant effect measures from the given data.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>For the data obtained from cross-over trials, we planned to carry out a paired analysis if possible, as this is the preferred method of analysis. As these data were not available from any of the trials included in the review, we used data presented in the original papers which were combined from both treatment and control arms of the trials, thereby ignoring the cross-over design. We included such data in the meta-analysis, which may be considered to be justified but unsatisfactory. This should be taken into account when considering the results of this review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>With regard to loss to follow up cases, only cases available for intention-to-treat analysis were evaluated. We made an attempt to contact the authors to obtain any missing data, such as standard deviation, if this could not be calculated from the available information in the report.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>We planned to use the I<SUP>2 </SUP>statistic with a significance threshold of alpha = 0.1 to test for heterogeneity. As per the protocol, if needed, we planned to consider the following factors as possible sources of heterogeneity:</P>
<UL>
<LI>differences in baseline characteristics of the study patients;</LI>
<LI>quality of studies;</LI>
<LI>adjuvant therapy permitted versus no adjuvant therapy.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-07-31 08:57:23 -0400" MODIFIED_BY="Karin L Dearness">
<P>For the assessment of publication bias, if sufficient data were available we planned to construct a funnel plot. However, in view of the different endpoints used in the studies, none of which allowed for the construction of funnel plot, this could not be undertaken.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>For continuous data, we calculated pooled standardised mean difference. We extracted the mean and standard deviation of each group. We used these values to calculate the standardised mean difference (SMD) with 95% confidence interval (CI). We planned to pool the odds ratio (OR) of individual studies using a random or fixed-effect model. No evaluable dichotomous outcomes were available for analysis and hence the methods for evaluation of dichotomous outcomes, as outlined in the protocol, were not utilised. We used RevMan (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) for all statistical analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>We planned a subgroup analysis for the following aetiological categories: alcohol-induced and idiopathic pancreatitis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>We also planned a sensitivity analysis in order to evaluate heterogeneity amongst the studies.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-08-11 09:34:34 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY_DESCRIPTION MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<SEARCH_RESULTS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>Ten studies met the criteria for inclusion in the review. These studies included a total of 361 patients. Six of these studies (<LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>; <LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>; <LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>; <LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>) compared enteric coated pancreatic enzyme preparations with placebo; one compared non-enteric coated granules (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>); two studies (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>; <LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>) compared different pancreatic enzyme preparations and one study evaluated the effect of administration schedule on the therapeutic efficacy of oral enzyme supplementation (<LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>).</P>
<P>The preparation of pancreatic enzymes used were different in the various studies. While in one study non-enteric coated pancreatic enzyme granules (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>) were used, in another (<LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>) acid protected porcine pancreatic enzyme was used. Six studies evaluated pancreatic microspheres (<LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>; <LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>; <LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>; <LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>). One study (<LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>) compared conventional enzyme preparation with or without cimetidine and an acid-protected enzyme preparation. Another study (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>) compared a conventional high lipase preparation with an equivalent dose of enteric coated enzyme supplement.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>All studies were randomised, controlled studies, eight of which were of cross-over design (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>; <LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>; <LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>; <LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>; <LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>) and the remainder were parallel group studies (<LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>; <LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>). The duration of follow up of the studies varied from five days to four months. In all the studies a washout period was mentioned and was adequate with respect to the duration of follow up.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>We excluded eleven studies because they were either non-randomised or did not satisfy the inclusion criteria.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-08-10 11:14:16 -0400" MODIFIED_BY="Karin L Dearness">
<P>A summary of the assessed risks of bias are provided in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2009-07-29 11:03:55 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Allocation concealment was adequate in four studies (<LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>; <LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>) but was not clear in the remaining six studies (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>; <LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>; <LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>; <LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>Seven studies were conducted in a double-blind manner (<LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>; <LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>; <LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>; <LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>) while two were open (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>; <LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>). In one study the authors mention having used a matching placebo but the blinding status is not clearly mentioned (<LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>Number of drop-outs, withdrawals and loss to follow up were incompletely described in all the studies. Analysis was carried out by the intention-to-treat method in three studies (<LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>; <LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>; <LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>) while it was not undertaken in two (<LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>; <LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>) and it was not clear in the remaining studies (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>; <LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>). All the studies described the results outlined in the methods sections. However, due to the unavailability of standard deviations or other relevant data, we could not pool the results for the majority of the outcomes. None of the studies evaluated all of the outcomes</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>It is possible that trials with statistically non-significant results have not been reported. This could not be assessed as we could not construct a funnel plot due to paucity of data</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>Type and schedule of administration was comparable between the groups in all the studies except one (<LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>) in which the aim of the study did not allow this assessment to be made. Thus, while no study was category A, five studies (<LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>; <LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>; <LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995;</LINK> <LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>) were classified as category B, while the rest were classified as category C studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-08-11 09:34:34 -0400" MODIFIED_BY="Karin L Dearness">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 01: Pancreatic enzyme compared with placebo</HEADING>
<P>The following outcomes were evaluated for this comparison:</P>
<SUBSECTION>
<HEADING LEVEL="4">01-Frequency of abdominal pain</HEADING>
<P>We identified no study which reported the frequency of abdominal pain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">02-Duration of pain episode</HEADING>
<P>We identified no study which reported the duration of pain episodes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">03-Intensity of pain</HEADING>
<P>Two studies (<LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>; <LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>) were identified which presented pain scores as mean and standard deviation. However, the scales used for scoring of pain were different. In one study (<LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>) a 0 to 3 score was used and for the other (<LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>) 0 to 5 scale was used. Due to the differences in the scale, we did not pool the data for these studies. Three other studies also reported intensity of pain scores. In one study (<LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>) the pain score was categorized as 1 to 5 and only mean values were given without standard deviation. In the other study (<LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>) the results were expressed as median values, while in the third study (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>) only the sum of scores was given. These results could not be pooled.</P>
<P>In the study by Mossner et al, there was a non-significant improvement in the pain scores with enzyme treatment (1.26 +/- 0.89) as compared to placebo treatment (1.08 +/- 0.87) (<LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>). In the study by Larvin et al, the pain scores were significantly different on treatment with enteric coated pancreatic microspheres (1.93 +/- 1.04) as compared to the placebo treatment (2.05 +/- 0.82) (<LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>). In the third study, the postprandial pain scores between the two treatment periods (pancreatic enzyme (4.6) and placebo (6.4)) were not significantly different (<LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>). In the study done by Malesci et al, there was a significant reduction in the cumulative pain score (median 95; range 0 to 1005, versus 134; 0 to 972; P &lt; 0.05) in the treatment phase with pancreatic enzyme as compared to the treatment phase with placebo (<LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>). Isaksson et al, have also shown a significant improvement in the pain score with pancreatic enzyme treatment as compared to the placebo treatment (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">04-Analgesic use</HEADING>
<P>Four studies reported analgesic use. However, in view of missing SD values the data could not be tabulated. In the first of these studies (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>) analgesic consumption was shown to be decreased (7.8 tablets during the enzyme treatment period versus 8.9 tablets during the placebo treatment period). In the second study (<LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>), analgesic consumption score was non-significantly decreased in the enzyme treated group as compared to the placebo group. The authors have presented the results for chronic pancreatitis patients with and without steatorrhoea. In the former group analgesic consumption score (stratified in accordance with their potency from 1 to 4) was 49 in the pancreatic enzyme as compared to 58 in the control; similarly figures for the patients with chronic pancreatitis without steatorrhoea show the analgesic consumption score was 57 in the pancreatic enzyme group and 48 in the placebo group. In the third study (<LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>), mean daily analgesic use was 51 mg during placebo and 45 mg during pancreatic enzyme treatment, the difference being statistically non-significant. In the fourth study (<LINK REF="STD-Malesci-1995" TYPE="STUDY">Malesci 1995</LINK>) the median score of analgesic consumption, corrected for drug potency, was higher although not statistically different, during enzyme therapy (12) than during placebo (0).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">05-Weight loss</HEADING>
<P>Two studies (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>; <LINK REF="STD-Larvin-1991" TYPE="STUDY">Larvin 1991</LINK>) including a total of 97 patients evaluated weight loss (kg). There was a greater weight loss in the control as compared to the pancreatic enzyme treated period; the difference being non-significant (SMD 0.06; 95% CI -0.23 to 0.34).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">06-Steatorrhoea</HEADING>
<P>We identified no study which reported presence or absence of steatorrhoea.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">07-Amount of faecal fat</HEADING>
<P>Four studies (<LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>; <LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>; <LINK REF="STD-O_x0027_Keefe--2001" TYPE="STUDY">O'Keefe 2001</LINK>; <LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>) were identified which reported faecal fat in grams per day. However, data for only two studies could be pooled. Pancreatic enzyme supplementation showed a significant decrease in the amount of faecal fat (g/day) as compared to placebo (SMD -1.03; 95% CI -1.60 to -0.46). In the third study (<LINK REF="STD-Halgreen-1986" TYPE="STUDY">Halgreen 1986</LINK>), for the chronic pancreatitis with steatorrhoea group, mean faecal weight was shown to decrease significantly when treated with pancreatic enzyme (10.4) as compared to the placebo-treated period (24.2). In the subgroup of chronic pancreatis patients without steatorrhoea, there was a non-significant increase in average faecal weight (63) when treated with enzyme as compared to the period when placebo was administered (58). However, since the authors did not provide the SD values the results could not be tabulated. In the fourth study (<LINK REF="STD-Mossner-1992" TYPE="STUDY">Mossner 1992</LINK>), the findings for faecal fat have only been represented graphically and no mean or standard values could be obtained.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">08-Change in quality of life scores</HEADING>
<P>One study evaluated the effect of pancreatic enzyme supplementation on a Clinical Global Impression of Disease Symptoms Scale as compared to placebo (<LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>). After two weeks of the double blind treatment phase, there was no significant difference in subjects' symptom scales (SMD -0.63; 95% CI -1.41 to 0.14). The authors noted a statistically significant improvement in the physician Clinical Global Impression of Disease Symptoms Scale in the enzyme supplementation group as compared to placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 02: Comparison of different dosage schedules</HEADING>
<P>In the only study (<LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>) in which different dosage schedules were compared, the outcomes of frequency of abdominal pain, duration of pain episode, intensity of pain, analgesic use, weight loss and changes in quality of life were not reported. The authors were contacted to provide the pertinent data in case they had been evaluated but not reported. However, as we failed to obtain any response, we report the main outcome of <SUP>13</SUP> CO<SUB>2</SUB> recovery in the breath test in the present review. Schedules of drug administration in which pancreatic enzymes were supplemented just after meals or along with meals (one capsule before, two during and one just after meals) were found to improve the mean (SD) six-hour cumulative recovery rate of <SUP>13</SUP> CO<SUB>2</SUB> (61.4% (21.4) and 60.6% (21.8), respectively) as compared to the schedule in which enzyme supplementation was done just before meals (53.9% (20.3)). However, the difference was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 03: Comparison of different enzyme preparations</HEADING>
<P>Two studies were included in this category (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>; <LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">01-Change in the incidence of steatorrhoea</HEADING>
<P>One study (<LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>) compared a conventional pancreatic enzyme preparation with an acid protected enzyme but presented the data for effect on steatorrhoea in a format which could not be utilised for the present analysis. The authors do report that there was no significant difference between the periods when patients received conventional pancreatic enzymes and when they received the acid protected enzyme preparation.</P>
<P>The second study (<LINK REF="STD-Delhaye--1996" TYPE="STUDY">Delhaye 1996</LINK>) evaluated a high lipase (HL) dose enteric coated enzyme supplement with a standard lipase dose, enteric-coated enzyme supplement. While the HL preparation was given as a single capsule with each meal resulting in 25,000 U of lipase with each meal, the standard lipase preparation contained 8000 U of lipase and was given as three capsules with each meal. As a consequence, the enzymatic content of the two preparations was almost similar. The authors noted no significant difference in the amount of faecal fat with the two enzyme preparations (SMD 0.13; 95% CI -0.42 to 0.69).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>The majority of the studies included in this review used a cross-over design. These studies included very small numbers of patients and only short-term follow-up data were available. The latest study dates from 2006 and the earliest from 1983. The diagnostic criteria for and management of chronic pancreatitis patients has undergone some changes during this period. Moreover, the trials varied widely in their reporting of the study findings. This could be due to lack of standard format for reporting of clinical trials in chronic pancreatitis. For example, the use of different scales for assessment of pain precluded the pooling of data for this important outcome. The authors of the studies were asked to provide the data which could be incorporated in our analysis, however most expressed their inability to provide these.</P>
<P>For the comparison of pancreatic enzyme versus placebo, all studies except one (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>) used enteric coated pancreatic enzyme preparations. The preparations also varied in their enzymatic contents. Only one study (<LINK REF="STD-Isaksson-1983" TYPE="STUDY">Isaksson 1983</LINK>) compared a conventional enzyme preparation with placebo. The concomitant medications used in this analysis were not clearly outlined in the studies.</P>
<P>Only one study could be identified in which different dosage schedules of pancreatic enzymes were evaluated (<LINK REF="STD-Dominguez_x002d_Munoz-2005" TYPE="STUDY">Dominguez-Munoz 2005</LINK>). The study was small and an intervention period of one week for each dosage schedule cannot be considered as adequate. Again, a single study was identified in which a comparison of conventional pancreatic enzyme preparations and acid protected microspheres was made (<LINK REF="STD-Lankisch-1986" TYPE="STUDY">Lankisch 1986</LINK>). However, the quality of this study, assessed as described above, was poor. It was a small study conducted in eight patients and the outcomes of faecal weight and faecal fat were not expressed in a format which allowed these to be included in our review. The other important outcomes, such as change in pain scores and analgesic use, were not evaluated.</P>
<P>No clinical trial evaluated any long-term outcome. Moreover, quality of life was also evaluated in only one of the trials (<LINK REF="STD-Safdi--2006" TYPE="STUDY">Safdi 2006</LINK>). Though the effect of pancreatic enzyme replacement therapy on quality of life in chronic pancreatitis patients was assessed in another study (<LINK REF="STD-Czako-2002" TYPE="STUDY">Czako 2002</LINK>), it did not satisfy our inclusion criteria so was excluded from the present analysis.</P>
<P>We could not undertake the subgroup analysis as planned. No study had categorised the patients on the basis of aetiology. Since the number of trials was small and very few outcomes could be entered into RevMan, we did not carry out a sensitivity analysis in order to check the robustness of study results. Further, we cannot comment on publication bias. None of the parameters had a sufficient number of studies for the data to be used to construct a funnel plot.</P>
<P>A relative lack of standardised outcomes, primary or secondary, prevented us from pooling the results of several outcomes. Again, missing standard deviation or error values or 95% confidence intervals in studies reflects upon the poor quality of data analysis.</P>
<P>In conclusion, no strong evidence exists for recommending pancreatic enzyme treatment for either the alleviation of pain or the reduction of steatorrhoea in patients with chronic pancreatitis. Further, no evidence exists for the effect of pancreatic enzymes on quality of life. Lastly, from the available evidence it cannot be conclusively shown that any one of the enzyme preparations, enteric or non-enteric coated, should be preferred over any other.
<BR/>

</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<IMPLICATIONS_PRACTICE MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>Based on this review, the use of pancreatic enzyme supplements (enteric coated or non-enteric coated) is not of any benefit in reducing the symptom of pain or steatorrhoea in patients with chronic pancreatitis. Since no study evaluated long-term outcomes or quality of life, the evidence for benefit of pancreatic enzyme preparations on these parameters is also lacking.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>There is a strong need for sufficiently powered, randomised clinical trials comparing pancreatic enzymes with placebo, preferably with government funding. Outcomes such as effect on pain scores (a more comprehensive scoring system such as Izbicki could be used), steatorrhoea, need for hospitalisation, development of complications and mortality need to be evaluated. Quality of life should be a component of secondary outcomes. Based on clinically relevant subgroups, stratified randomisation could be used in the study design in order to enable subgroup analysis. Once the efficacy (or otherwise) of pancreatic enzymes over placebo is established then subsequent studies to compare different doses, formulations, or both, should be carried out.
<BR/>

</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>We wish to acknowledge the help extended to us by the Cochrane UGPD Group, especially Cathy Bennett for the continuous guidance provided to us in the conduct of this review. We wish to thank Rosemary Campbell-Blair, for helping us with the literature search for this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None declared.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>Conceiving the review: Dr Samir Malhotra, Dr Nusrat Shafiq<BR/>Designing the review: Dr Nusrat Shafiq, Dr S. Malhotra<BR/>Co-ordinating the review: Prof P Pandhi, Prof DK Bhasin<BR/>Data collection for the review: Dr Nusrat Shafiq, Dr Surjit S Sehmby, Mr Raj Kumar<BR/>Designing search strategies: Rosemary Campbell-Blair.<BR/>Undertaking searches: Rosemary Campbell-Blair, Dr Nusrat Shafiq<BR/>Screening search results: Dr Nusrat Shafiq, Dr Puja Srivastava, Dr Surjit S Sehmby<BR/>Organising retrieval of papers: Mr Raj Kumar<BR/>Screening retrieved papers against inclusion criteria: Dr Nusrat Shafiq, Dr Puja Srivastava, Dr Surinder Rana<BR/>Appraising quality of papers: Dr Nusrat Shafiq, Dr Samir Malhotra, Dr Puja Srivastava<BR/>Extracting data from papers: Dr Nusrat Shafiq, Dr Samir Malhotra, Dr S.Sehmby<BR/>Writing to authors of papers for additional information: Dr Nusrat Shafiq<BR/>Providing additional data about papers: Mr Raj Kumar<BR/>Obtaining and screening data on unpublished studies: Dr Nusrat Shafiq<BR/>Data management for the review: Dr Nusrat Shafiq, Dr Samir Malhotra, Dr Surjit S Sehmby<BR/>Entering data into RevMan: Dr Nusrat Shafiq, Dr Samir Malhotra, Dr Puja Srivastava<BR/>Analysis of data: Dr Nusrat Shafiq, Dr Samir Malhotra<BR/>Interpretation of data: Dr Nusrat Shafiq, Dr Samir Malhotra<BR/>Providing a methodological perspective: Dr Nusrat Shafiq,Dr Samir Malhotra<BR/>Providing a clinical perspective: Prof DK Bhasin, Dr Surinder Rana, Dr Puja Srivastava<BR/>Providing a policy perspective: Dr Samir Malhotra, Prof P Pandhi, Prof DK Bhasin<BR/>Providing a consumer perspective: Prof P.Pandhi<BR/>Writing the review: Dr Nusrat Shafiq, Dr Samir Malhotra<BR/>Providing general advice on the review: Dr Nusrat Shafiq, Dr Samir Malhotra, Prof P.Pandhi, Prof DK Bhasin</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-07-31 09:11:52 -0400" MODIFIED_BY="Karin L Dearness">
<STUDIES MODIFIED="2009-07-31 08:58:37 -0400" MODIFIED_BY="Karin L Dearness">
<INCLUDED_STUDIES MODIFIED="2009-07-31 08:58:08 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY DATA_SOURCE="PUB" ID="STD-Delhaye--1996" MODIFIED="2009-07-02 11:14:23 -0400" MODIFIED_BY="Karin L Dearness" NAME="Delhaye  1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-02 11:14:23 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delhaye M, Meuris S, Gohimont AC, Buedts K, Cremer M</AU>
<TI>Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1996</YR>
<VL>8</VL>
<PG>699-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominguez_x002d_Munoz-2005" MODIFIED="2009-07-02 11:14:32 -0400" MODIFIED_BY="Karin L Dearness" NAME="Dominguez-Munoz 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-02 11:14:32 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-Insua M</AU>
<TI>Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three-way crossover study</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2005</YR>
<VL>21</VL>
<PG>993-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halgreen-1986" NAME="Halgreen 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halgreen H, Pederson NT, Worning H</AU>
<TI>Symptomatic effect of pancreatic enzyme therapy in patients with chronic pancreatitis</TI>
<SO>Scandinavian Journal of Gastroentrology</SO>
<YR>1986</YR>
<VL>21</VL>
<NO>1</NO>
<PG>104-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isaksson-1983" MODIFIED="2009-07-02 11:14:42 -0400" MODIFIED_BY="Karin L Dearness" NAME="Isaksson 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-07-02 11:14:42 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isaksson G, Ihse I</AU>
<TI>Pain reduction by an oral pancreatic enzyme preparation in chronic pancreatitis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1983</YR>
<VL>28</VL>
<PG>97-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lankisch-1986" NAME="Lankisch 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lankisch PG, Lembcke B, Goke B, Creutzfeldt W</AU>
<TI>Therapy of pancreatogenic steatorrhoea: does acid protection of pancreatic enzymes offer any advantage?</TI>
<SO>Zeitschrift fur Gastroenterologie</SO>
<YR>1986</YR>
<VL>24</VL>
<PG>753-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larvin-1991" NAME="Larvin 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larwin M, McMahon MJ, Thomas WEG, Puntis MCA</AU>
<TI>Creon (enteric coated pancreatin microspheres) for the treatment of pain in chronic pancreatitis: a double blind randomized placebo-controlled cross-over study</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>100</VL>
<PG>A283</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malesci-1995" MODIFIED="2009-06-17 11:59:41 -0400" MODIFIED_BY="Karin L Dearness" NAME="Malesci 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-06-17 11:59:41 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malesci A, Gaia E, Fioretta A, Bocchia P, Dirauenga G, Cantor P, et al</AU>
<TI>No effect of long term treatment with pancreatic extract on recurrent abdominal pain in patients with chronic pancreatitis</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>4</NO>
<PG>392-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mossner-1992" NAME="Mossner 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mossner J, Secknus R, Mayer J, Niedeau C, Adler G</AU>
<TI>Treatment of pain with pancreatic extracts in chronic pancreatitis: results of a prospective placebo-controlled multicenter trial</TI>
<SO>Digestion</SO>
<YR>1992</YR>
<VL>53</VL>
<PG>54-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Keefe--2001" MODIFIED="2009-03-31 05:01:17 -0400" MODIFIED_BY="[Empty name]" NAME="O'Keefe  2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-31 05:01:17 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Keefe SJ, Cariem AK, Levy M</AU>
<TI>The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>319-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Safdi--2006" MODIFIED="2009-07-31 08:58:08 -0400" MODIFIED_BY="Karin L Dearness" NAME="Safdi  2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-31 08:58:08 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F Toskes PP</AU>
<TI>The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis</TI>
<SO>Pancreas</SO>
<YR>2006</YR>
<VL>33</VL>
<PG>156-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-07-31 08:58:37 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY DATA_SOURCE="PUB" ID="STD-Benini-1991" MODIFIED="2009-07-02 10:50:17 -0400" MODIFIED_BY="Karin L Dearness" NAME="Benini 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-02 10:50:17 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benini L, Caliari S, Vaona B, Brocco G, Micciolo R, Rizzotti P, et al</AU>
<TI>Variations in time of serum pancreatic enzyme levels in chronic pancreatitis and clinical course of the disease</TI>
<SO>International Journal of Pancreatology</SO>
<YR>1991</YR>
<VL>8</VL>
<PG>279-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruno-1998" MODIFIED="2009-07-31 08:58:22 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bruno 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-07-31 08:58:22 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruno MJ, Borm JJ, Hoek FJ, Delzenne B, Hofmann AF, de Goeij JJ, et al</AU>
<TI>Gastric transit and pharmacodynamics of a two-millimeter enteric-coated pancreatin microsphere preparation in patients with chronic pancreatitis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>203-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czako-2002" MODIFIED="2009-07-02 10:50:37 -0400" MODIFIED_BY="Karin L Dearness" NAME="Czako 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-02 10:50:37 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czako L, Takacs T, Lonovics J, Lakner L, Dobronte Z, Pronai L, et al</AU>
<TI>Quality of life in the course of enzyme replacement therapy for chronic pancreatitis</TI>
<SO>Orvosi Hetilap</SO>
<YR>2002</YR>
<VL>143</VL>
<PG>1521-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gouerou-1989" MODIFIED="2009-07-31 08:58:37 -0400" MODIFIED_BY="Karin L Dearness" NAME="Gouerou 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-07-31 08:58:37 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gouerou H, Dain MP, Parrondo I, Poisson D, Bernades P</AU>
<TI>Alipase versus nonenteric-coated enzymes in pancreatic insufficiency. A French multicenter crossover comparative study</TI>
<SO>International Journal of Pancreatology</SO>
<YR>1989</YR>
<VL>5</VL>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madsen-2003" NAME="Madsen 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madsen JL, Graff J, Philipsen EK, Scharff O, Rumessen JJ</AU>
<TI>Bile acid malabsorption or disturbed intestinal permeability in patients treated with enzyme substitution for exocrine pancreatic insufficiency is not caused by bacterial overgrowth</TI>
<SO>Pancreas</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>130-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marotta-1989" MODIFIED="2009-07-02 10:51:38 -0400" MODIFIED_BY="Karin L Dearness" NAME="Marotta 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-07-02 10:51:38 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marotta F, O'Keefe SJ, Marks IN, Girdwood A, Young G</AU>
<TI>Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1989</YR>
<VL>34</VL>
<PG>456-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mizushima-2004" MODIFIED="2009-07-02 10:51:47 -0400" MODIFIED_BY="Karin L Dearness" NAME="Mizushima 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-02 10:51:47 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mizushima T, Ochi K, Ichimura M, Kiura K, Harada H, Koide N</AU>
<TI>Pancreatic enzyme supplement improves dysmotility in chronic pancreatitis patients</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>1005-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pasquali-C-1996" MODIFIED="2009-07-02 10:51:28 -0400" MODIFIED_BY="Karin L Dearness" NAME="Pasquali C 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-02 10:51:28 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pasquali C, Fogar P, Sperti C, Basso D, De Paoli M, Plebani M, et al</AU>
<TI>Efficacy of a pancreatic enzyme formulation in the treatment of steatorrhea in patients with chronic pancreatitis</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1996</YR>
<VL>57</VL>
<PG>358-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Regan-PT-1977" NAME="Regan PT 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Regan PT, Malagelada JR, DiMagno EP, Glanzman SL, Go VL</AU>
<TI>Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency</TI>
<SO>New England Journal of Medicine</SO>
<YR>1977</YR>
<VL>297</VL>
<PG>854-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1985" MODIFIED="2009-05-28 01:27:31 -0400" MODIFIED_BY="[Empty name]" NAME="Schneider 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-05-28 01:27:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider MU, Knoll-Ruzicka ML, Domschke S, Heptner G, Domschke W</AU>
<TI>Pancreatic enzyme replacement therapy: comparative effects of conventional and enteric-coated microspheric pancreatin and acid-stable fungal enzyme preparations on steatorrhoea in chronic pancreatitis</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>1985</YR>
<VL>32</VL>
<PG>97-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsujino-2005" MODIFIED="2009-07-02 10:52:34 -0400" MODIFIED_BY="Karin L Dearness" NAME="Tsujino 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-02 10:52:34 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al</AU>
<TI>Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>376-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vecht-J-2006" MODIFIED="2009-03-31 05:01:28 -0400" MODIFIED_BY="[Empty name]" NAME="Vecht J 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-31 05:01:28 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vecht J, Symersky T, Lamers CBHW, Masclee AAM</AU>
<TI>Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2006</YR>
<VL>40</VL>
<PG>721-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-06-13 01:11:02 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Paris-JC-1993" MODIFIED="2009-06-13 01:11:02 -0400" MODIFIED_BY="[Empty name]" NAME="Paris JC 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-06-13 01:11:02 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paris JC</AU>
<TI>A multicentre double-blind placebo-controlled study of the effect of a pancreatic enzyme formulation (Panzytrat(TM) 25 000) on impaired lipid digestion in adults with chronic pancreatitis</TI>
<SO>Drug Investigation</SO>
<YR>1993</YR>
<VL>54</VL>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-06-13 01:11:02 -0400" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-07-31 09:11:52 -0400" MODIFIED_BY="Karin L Dearness">
<ADDITIONAL_REFERENCES MODIFIED="2009-07-31 09:11:52 -0400" MODIFIED_BY="Karin L Dearness">
<REFERENCE ID="REF-AGA-1998" MODIFIED="2009-07-31 08:58:45 -0400" MODIFIED_BY="Karin L Dearness" NAME="AGA 1998" TYPE="JOURNAL_ARTICLE">
<AU>American Gastroenterological Association Clinical Practice and practice economics committee</AU>
<TI>Treatment of pain in chronic pancreatitis</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>115</VL>
<PG>765-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ammann-1999" MODIFIED="2009-07-29 11:48:49 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Ammann 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ammann RW, Muellhaupt B</AU>
<TI>The natural history of pain in alcoholic chronic pancreatitis</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>116</VL>
<PG>1132-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Behrman-2007" MODIFIED="2009-07-02 10:52:56 -0400" MODIFIED_BY="Karin L Dearness" NAME="Behrman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Behrman SW, Fowler ES</AU>
<TI>Pathophysiology of chronic pancreatitis</TI>
<SO>Surgical Clinics of North America</SO>
<YR>2007</YR>
<VL>87</VL>
<PG>1309-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhadada-2007" MODIFIED="2008-12-12 16:05:34 -0500" MODIFIED_BY="Karin L Dearness" NAME="Bhadada 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bhadada SK, Udawat HP, Bhansali A, Rana SS, Sinha SK, Bhasin DK</AU>
<TI>Chronic pancreatitis in primary hyperparathyroidism: comparison with alcoholic and idiopathic chronic pancreatitis</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>6</NO>
<PG>959-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhasin-2006" MODIFIED="2009-07-29 11:49:06 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Bhasin 2006" TYPE="BOOK_SECTION">
<AU>Bhasin DK, Singh G, Chowdhary S, Rana SS, Sinha SK, Nagi B</AU>
<TI>Profile of chronic pancreatitis at Postgraduate Institute of Medical Education and Research</TI>
<SO>Chronic pancreatitis and pancreatic diabetes in India</SO>
<YR>2006</YR>
<PG>81-90</PG>
<ED>Balakrishnan V, Harishkumar, Sudhindran S, Unnikrishnan AG</ED>
<PB>Indian Pancreatic Study Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1997" NAME="Brown 1997" TYPE="JOURNAL_ARTICLE">
<AU>Brown A, Hughes M, Tenner S, Banks PA</AU>
<TI>Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta-analysis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>11</NO>
<PG>2032-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruno-1995" MODIFIED="2009-07-31 09:11:52 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bruno 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bruno MJ, Haverkort EB, Tytgat GNJ, van Leeuwen DJ</AU>
<TI>Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause related and patient-tailored treatment [Review]</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1995</YR>
<VL>90</VL>
<PG>1383-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohn-1998" MODIFIED="2009-06-17 12:01:03 -0400" MODIFIED_BY="Karin L Dearness" NAME="Cohn 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cohn JA, Friedman KJ, Noone PG</AU>
<TI>Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>653-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Copenhagen-1981" MODIFIED="2009-07-31 08:58:54 -0400" MODIFIED_BY="Karin L Dearness" NAME="Copenhagen 1981" TYPE="JOURNAL_ARTICLE">
<AU>Copenhagen Pancreatitis Study Group</AU>
<TI>Copenhagen Pancreatitis Study: an interim report from a prospective multicentre epidemiological multicentre study</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1981</YR>
<VL>16</VL>
<PG>305-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Czack-2003" MODIFIED="2009-07-02 10:53:18 -0400" MODIFIED_BY="Karin L Dearness" NAME="Czack 2003" TYPE="JOURNAL_ARTICLE">
<AU>Czack OL, Takacs T, Hegyi, Pronai L, Tulassay Z, Lakner L, et al</AU>
<TI>Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis</TI>
<SO>Canadian Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>597-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dominguez-2005" MODIFIED="2009-07-02 10:53:32 -0400" MODIFIED_BY="Karin L Dearness" NAME="Dominguez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M, Figueiras A, Vilarino-Insua M</AU>
<TI>Effect of administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized three way cross over study</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2005</YR>
<VL>21</VL>
<PG>993-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Etemad-2001" MODIFIED="2009-07-31 08:59:05 -0400" MODIFIED_BY="Karin L Dearness" NAME="Etemad 2001" TYPE="JOURNAL_ARTICLE">
<AU>Etemad B, Whitcomb D</AU>
<TI>Chronic pancreatitis: diagnosis, classification and new genetic developments</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120</VL>
<PG>682-707</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2004" MODIFIED="2009-07-31 09:11:25 -0400" MODIFIED_BY="Karin L Dearness" NAME="FDA 2004" TYPE="OTHER">
<AU>U.S. Department of Health and Human Services Food and Drug Administration (FDA), Centre for Drug Evaluation and Research (CDER)</AU>
<TI>Guidance for Industry exocrine pancreatic insufficiency drug products - submitting NDAs: draft guidance</TI>
<SO>http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0206-gdl0001.pdf</SO>
<YR>(accessed 31 July 2009)</YR>
<IDENTIFIERS MODIFIED="2009-07-29 11:51:40 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Frey-1990" MODIFIED="2009-06-17 12:01:42 -0400" MODIFIED_BY="Karin L Dearness" NAME="Frey 1990" TYPE="JOURNAL_ARTICLE">
<AU>Frey CF, Suzuki M, Isaji S</AU>
<TI>Treatment of chronic pancreatitis complicated by obstruction of the common bile duct or duodenum</TI>
<SO>World Journal of Surgery</SO>
<YR>1990</YR>
<VL>14</VL>
<PG>59-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberger-1999" NAME="Greenberger 1999" TYPE="JOURNAL_ARTICLE">
<AU>Greenberger NJ</AU>
<TI>Enzymatic therapy in patients with chronic pancreatitis</TI>
<SO>Gastroenterology Clinics of North America</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>687-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberger-2005" MODIFIED="2009-07-31 08:59:13 -0400" MODIFIED_BY="Karin L Dearness" NAME="Greenberger 2005" TYPE="BOOK_SECTION">
<AU>Greenberger NJ, Toskes PP</AU>
<TI>Acute and chronic pancreatitis</TI>
<SO>Harrison's Principles of International Medicine Textbook</SO>
<YR>2005</YR>
<PG>1895-1903</PG>
<EN>16th</EN>
<ED>Kasper DL, Braunwald E, Fauci A, Hauser S, Longo D, Jameson JL</ED>
<PB>McGraw-Hill Professional</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 0071402357"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2009-07-31 08:59:23 -0400" MODIFIED_BY="Karin L Dearness" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 4.2.5 [updated May 2005]. The Cochrane Collaboration</SO>
<YR>2005</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hsu-2005" MODIFIED="2009-07-02 10:53:53 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hsu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hsu TJ, Yeh CN, Chen YR, Chen HM, Hwang TL, Jan YY, et al</AU>
<TI>Adenosquamous carcinoma of the pancreas</TI>
<SO>Digestion</SO>
<YR>2005</YR>
<VL>72</VL>
<PG>104-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalthoff-1984" MODIFIED="2009-06-17 12:02:02 -0400" MODIFIED_BY="Karin L Dearness" NAME="Kalthoff 1984" TYPE="CONFERENCE_PROC">
<AU>Kalthoff L, Layer P, Clain JE</AU>
<TI>The course of alcoholic and nonalcoholic chronic pancreatitis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1984</YR>
<VL>29</VL>
<PG>953</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiraly-2007" MODIFIED="2009-07-29 11:52:37 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Kiraly 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kiraly O, Boulling A, Witt H</AU>
<TI>Signal peptide variants that impair secretion of pancreatic secretory trypsin inhibitor (SPINK1) cause autosomal dominant hereditary pancreatitis</TI>
<SO>Human Mutation</SO>
<YR>2007</YR>
<VL>28</VL>
<PG>469-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kloppel-1992" MODIFIED="2009-07-31 08:59:35 -0400" MODIFIED_BY="Karin L Dearness" NAME="Kloppel 1992" TYPE="JOURNAL_ARTICLE">
<AU>Kloppel G, Mailet B</AU>
<TI>The morphological basis for the evolution of acute pancreatitis into chronic pancreatitis</TI>
<SO>Virchows Archiv. A, Pathological Anatomy and Histopathology</SO>
<YR>1992</YR>
<VL>420</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Layer-1994" MODIFIED="2009-07-29 11:52:46 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Layer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, Di Magno EP</AU>
<TI>The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>107</VL>
<PG>1481-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2007" MODIFIED="2009-07-30 11:26:25 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Lee 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lee JK, Enns R</AU>
<TI>Review of idiopathic pancreatitis</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>6296-313</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owyang-1991" NAME="Owyang 1991" TYPE="BOOK_SECTION">
<AU>Owyang C, Levitt M</AU>
<TI>Chronic pancreatitis</TI>
<SO>Textbook of Gastroenterology</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>1874-93</PG>
<ED>Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE</ED>
<PB>J.B. Lippincott</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-07-31 08:59:49 -0400" MODIFIED_BY="Karin L Dearness" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandberg-1989" MODIFIED="2009-06-17 12:04:25 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sandberg 1989" TYPE="JOURNAL_ARTICLE">
<AU>Andren-Sandberg A</AU>
<TI>Theory and practice in the individualization of oral pancreatic enzyme administration for chronic pancreatitis</TI>
<SO>International Journal of Pancreatology</SO>
<YR>1989</YR>
<VL>5</VL>
<NO>Suppl</NO>
<PG>51-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schnelldorfer-2008" MODIFIED="2009-06-17 12:04:37 -0400" MODIFIED_BY="Karin L Dearness" NAME="Schnelldorfer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Schnelldorfer T, Adams DB</AU>
<TI>Surgical treatment of alcohol associated chronic pancreatitis: the challenges and pitfalls</TI>
<SO>American Surgeon</SO>
<YR>2008</YR>
<VL>74</VL>
<PG>503-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slaff-1984" NAME="Slaff 1984" TYPE="JOURNAL_ARTICLE">
<AU>Slaff J, Jacobson D, Tillman CR, Curington C, Toskes P</AU>
<TI>Protease-specific suppression of pancreatic exocrine secretion</TI>
<SO>Gastroenterology</SO>
<YR>1984</YR>
<VL>87</VL>
<PG>44-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steer-1995" MODIFIED="2009-07-30 11:26:34 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Steer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Steer ML, Waxman I, Freedman S</AU>
<TI>Chronic pancreatitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>22</NO>
<PG>1482-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitcomb-1996" MODIFIED="2009-06-17 12:06:17 -0400" MODIFIED_BY="Karin L Dearness" NAME="Whitcomb 1996" TYPE="JOURNAL_ARTICLE">
<AU>Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al</AU>
<TI>Hereditary pancreatitis is caused by a mutation in the cationic trysionogen gene</TI>
<SO>Nature Genetics</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>2</NO>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Witt-2005" MODIFIED="2009-06-17 12:05:10 -0400" MODIFIED_BY="Karin L Dearness" NAME="Witt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Witt H, Luck W, Hennies HC</AU>
<TI>Mutations in the gene encoding the serine protease inhibitor, Kazal type I, are associated with chronic pancreatitis</TI>
<SO>Nature Genetics</SO>
<YR>2000</YR>
<VL>25</VL>
<PG>213-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-10 11:12:07 -0400" MODIFIED_BY="Karin L Dearness">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-10 11:12:07 -0400" MODIFIED_BY="Karin L Dearness" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Delhaye--1996">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:24 -0400" MODIFIED_BY="Karin L Dearness">
<P>Open, cross-over, prospective study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-30 02:54:27 -0400" MODIFIED_BY="[Empty name]">
<P>Chronic pancreatitis with steatorrhoea</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Pancrease HL (25,000 U lipase), 3 capsules/day, pancreatic enzyme containing microspheres (8000 U lipase), 9 capsules/day, with or without omeprazole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Faecal fat, protein and energy excretion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Authors noted that use of omeprazole did not significantly alter the faecal fat, protein or energy excretion</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Dominguez_x002d_Munoz-2005">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, open, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-31 05:04:10 -0400" MODIFIED_BY="[Empty name]">
<P>Severe chronic pancreatitis with steatorrhoea</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Three different administration schedules of enteric coated microspheric enzyme preparations with 10,000 U lipase in each capsule. The 3 schedules were:</P>
<P>Schedule A: 4 capsules just before meals; Schedule B: 4 capsules just after meals; Schedule C: 1 capsule just before meals, 2 during and 1 just after meals</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>6-hour cumulative recovery rate of <SUP>13</SUP> CO<SUB>2 </SUB>as measured by the <SUP>13</SUP>C-MTG-breath test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-31 06:14:22 -0400" MODIFIED_BY="[Empty name]">
<P>Each treatment schedule was administered for a week</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Halgreen-1986">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, double blind, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult chronic pancreatitis patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Encapsulated enteric-coated microspheric enzyme preparation containing 4000 National Formulary Units (NFU) lipase, 20,000 NFU amylase and 25,000 NFU proteases or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-17 11:58:55 -0400" MODIFIED_BY="Karin L Dearness">
<P>1. Faecal fat (g/day)<BR/>2. Faecal weight (g/day)<BR/>3. Postprandial pain score<BR/>4. Subjective pain score<BR/>5. Analgesic consumption</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Results were stratified according to those with and without steatorrhoea. Patients were followed up for a period of 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Isaksson-1983">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, double blind, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult chronic pancreatitis patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Conventional (non-enteric coated) pancreatic enzyme granules, 7.5 ml 5 times daily or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Body weight<BR/>2. Steatorrhoea<BR/>3. Pain scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>For pain scores patients were stratified into good and poor responders. The total follow-up period was 2 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Lankisch-1986">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult chronic pancreatitis patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>1. Conventional enzyme preparation, 3 x 3 dragees daily<BR/>2. Pankreon 700, 3 x 3 dragees daily, plus cimetidine 300 mg, 30 minutes prior to the 3 main meals<BR/>3. Kreon 3 x 6 capsules daily</P>
<P>Pancreatin (6.3 g/day for regimes 1 and 2; 5.4 g/day for regimen 3); lipase (252,000 FIP units/day for regimes 1 and 2;180,000 FIP units/day for regimen 3) were comparable</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Faecal weight<BR/>2. Faecal fat</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The study compared different pancreatic enzyme preparations. The duration of follow up for each of the treatment periods was 5 days.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Larvin-1991">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult chronic pancreatitis patients without steatorrhoea</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Enteric coated enzyme preparations (3 capsules, 4 times daily) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>1. Pain severity score<BR/>2. Pain frequency/duration index<BR/>3. Rescue analgesic consumption<BR/>4. Weight loss</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The study results are available as abstracts only and detailed description of the study methodology could not be obtained. The duration of follow up was for a period of 8 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Malesci-1995">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, double blind, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult chronic pancreatitis patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Pancreatic extract (capsules of enteric coated microspheres, each capsule containing 34,375 USP of protease, 13,000 USP units of lipase and 43, 570 units of amylase)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Patients' record of pain on a 10 cm linear visual analogue scale which was scored from 1 to 4 on a metric basis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Results were presented as median with range. The patients were followed up for a period of 4 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Mossner-1992">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, double blind, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult chronic pancreatitis patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>Acid protected pancreatic extract capsules given 5 x 2 capsules/day with each capsule containing triacylglycerol lipase 20,000 Ph Eur U, amylase 18,000 Ph Eur U, proteases 1000 Ph Eur U</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 08:57:25 -0400" MODIFIED_BY="Karin L Dearness">
<P>1. Pain score recorded on a 0 to 3 scale with 0 indicating no pain and 3 very severe pain<BR/>2. No of patients with possible acute relapse<BR/>3. Serum amylase and gamma-glutamyl transferase levels<BR/>4. Faecal fat excretion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>The total follow-up period was 2 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-O_x0027_Keefe--2001">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, parallel group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-29 11:43:46 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Adult chronic pancreatitis patients with documented evidence of disturbed pancreatic exocrine function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Pancreatic enzyme containing mini-microspheres containing lipase 10,000 USP U, amylase 33,200 U and proteases 37,500 USP U. 4 capsules were given with each full meal and 2 were given with snacks. Matching placebo was given to the comparator arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-29 11:44:01 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Coefficient of fat and protein absorption, stool weight, stool fat excretion, stool nitrogen extent</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Statistically significant differences were noted for the baseline variables of age, body weight, body mass index and diabetes in the 2 groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Safdi--2006">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, double blind, placebo-controlled, parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-23 02:18:24 -0400" MODIFIED_BY="[Empty name]">
<P>Adults with chronic pancreatitis and history of pancreatic exocrine insufficiency</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Enteric coated minimicrospheres containing 10,000 U of lipase, 37,500 U of protease and 33,200 U of amylase, administered as 4 capsules with each meal and 2 capsules with snacks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Coefficient of fat absorption, daily fat excretion, Clinical Global Impression of Disease Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>The duration of double blind treatment was 2 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>C-MTG = Radiocarbon Labelled Mixed Triglyceride Breath Test<BR/>FIP = Fungi Lipase International, units for measuring pancreatic enzyme activity<BR/>NFU = National Formulary Units</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Benini-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Bruno-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Czako-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Gouerou-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Madsen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised, different objectives</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Marotta-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mizushima-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not satisfy inclusion criteria (comparison of healthy and chronic pancreatitis patients)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Pasquali-C-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Regan-PT-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Schneider-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsujino-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Different drug (protease inhibitor)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-25 10:15:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vecht-J-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-25 10:15:28 -0400" MODIFIED_BY="[Empty name]">
<P>Protease inhibitor given with low and high dose of pancreatic enzyme supplementation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Paris-JC-1993">
<CHAR_METHODS MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness">
<P>Double blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-29 11:47:26 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Chronic alcoholic pancreatitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness">
<P>Panzytrat 25,000, 2 capsules given 3 times daily or placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-13 01:14:35 -0400" MODIFIED_BY="[Empty name]">
<P>Panzytrat reduced steatorrhoea and stool weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-31 08:57:27 -0400" MODIFIED_BY="Karin L Dearness">
<P>The study will be assessed in detail in any future updates of the review if authors provide the requested information</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-06-13 01:11:02 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-10 11:12:07 -0400" MODIFIED_BY="Karin L Dearness">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-30 02:58:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Delhaye--1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-31 06:21:54 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dominguez_x002d_Munoz-2005">
<DESCRIPTION>
<P>The corresponding sequence was concealed until intervention was assigned. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halgreen-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Isaksson-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lankisch-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Larvin-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Malesci-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mossner-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keefe--2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-31 08:57:26 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Safdi--2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-08-10 11:12:03 -0400" MODIFIED_BY="Karin L Dearness" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:03:11 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Delhaye--1996">
<DESCRIPTION>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:08:32 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dominguez_x002d_Munoz-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:08:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Halgreen-1986">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:09:55 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Isaksson-1983">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Lankisch-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Larvin-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:11:21 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Malesci-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:11:14 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Mossner-1992">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:11:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-O_x0027_Keefe--2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-10 11:12:03 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Safdi--2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-08-10 11:12:04 -0400" MODIFIED_BY="Karin L Dearness" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-10 11:08:15 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Delhaye--1996">
<DESCRIPTION>
<P>Data presented for 25 out of 32 patietns as the remaining patients did not complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-10 11:08:36 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Dominguez_x002d_Munoz-2005">
<DESCRIPTION>
<P>Not required</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-10 11:09:15 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Halgreen-1986">
<DESCRIPTION>
<P>Standard deviations or any other measure of dispersion not mentioned for several outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-10 11:09:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Isaksson-1983">
<DESCRIPTION>
<P>Data for one patient was not included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Lankisch-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Larvin-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-10 11:10:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Malesci-1995">
<DESCRIPTION>
<P>Data for four patients was not included in the final analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-10 11:11:26 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Mossner-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Keefe--2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-10 11:12:04 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Safdi--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-10 11:12:05 -0400" MODIFIED_BY="Karin L Dearness" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:05:25 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Delhaye--1996">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:08:39 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dominguez_x002d_Munoz-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:09:32 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Halgreen-1986">
<DESCRIPTION>
<P>Dropouts and withdrawals not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:09:59 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Isaksson-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lankisch-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Larvin-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Malesci-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:11:28 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Mossner-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:11:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-O_x0027_Keefe--2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:12:05 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Safdi--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-08-10 11:12:07 -0400" MODIFIED_BY="Karin L Dearness" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:05:53 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Delhaye--1996">
<DESCRIPTION>
<P>Possibility of bias due to lack of true intention to treat analysis may be present</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dominguez_x002d_Munoz-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:09:30 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Halgreen-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:10:11 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Isaksson-1983">
<DESCRIPTION>
<P>It is not clear if intention to treat analysis was undertaken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lankisch-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Larvin-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:11:01 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Malesci-1995">
<DESCRIPTION>
<P>Intention to treat analysis was not undertaken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:11:41 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Mossner-1992">
<DESCRIPTION>
<P>Intention to treat analysis was not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:11:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-O_x0027_Keefe--2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-10 11:12:07 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Safdi--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-29 08:45:22 -0400" MODIFIED_BY="Jenny Bellorini">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-29 08:45:03 -0400" MODIFIED_BY="Jenny Bellorini" NO="1">
<NAME>Pancreatic enzyme versus placebo</NAME>
<CONT_OUTCOME CHI2="0.9632039424259966" CI_END="0.33701722935263234" CI_START="-0.2267516796799622" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.05513277483633508" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2009-07-21 10:15:36 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.3263811592916217" P_Q="1.0" P_Z="0.701465933144787" Q="0.0" RANDOM="NO" SCALE="1.355645812126483" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="97" UNITS="" WEIGHT="99.99999999999999" Z="0.3833423635666489">
<NAME>Weight loss</NAME>
<GROUP_LABEL_1>Pancreatic enzyme</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9845690007591126" CI_START="-0.29764244018297775" EFFECT_SIZE="0.34346328028806744" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="61.0" ORDER="2" SD_1="2.9" SD_2="2.8" SE="0.3271007658957028" STUDY_ID="STD-Isaksson-1983" TOTAL_1="19" TOTAL_2="19" WEIGHT="19.33227425981444"/>
<CONT_DATA CI_END="0.2998828018328728" CI_START="-0.32781587763817416" EFFECT_SIZE="-0.013966537902650688" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="63.2" ORDER="1" SD_1="14.2" SD_2="14.3" SE="0.1601301565799816" STUDY_ID="STD-Larvin-1991" TOTAL_1="78" TOTAL_2="78" WEIGHT="80.66772574018555"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.21978920129812685" CI_END="-0.4588719161678074" CI_START="-1.597762660873461" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.0283172885206342" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2009-07-29 08:45:03 -0400" MODIFIED_BY="Jenny Bellorini" NO="2" P_CHI2="0.6392006001707337" P_Q="1.0" P_Z="4.01117999717256E-4" Q="0.0" RANDOM="NO" SCALE="2.250489884351816" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="3.539347140275908">
<NAME>Amount of faecal fat</NAME>
<GROUP_LABEL_1>Pancreatic enzyme</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1341118331294726" CI_START="-1.6744519888045004" EFFECT_SIZE="-0.9042819109669865" ESTIMABLE="YES" MEAN_1="20.3" MEAN_2="48.0" MODIFIED="2009-05-20 05:16:18 -0400" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="16.77" SD_2="39.22" SE="0.39295113783340774" STUDY_ID="STD-O_x0027_Keefe--2001" TOTAL_1="15" TOTAL_2="14" WEIGHT="54.66770630720939"/>
<CONT_DATA CI_END="-0.33213353377099397" CI_START="-2.023657738837391" EFFECT_SIZE="-1.1778956363041924" ESTIMABLE="YES" MEAN_1="18.6" MEAN_2="51.8" MODIFIED="2009-05-20 05:15:07 -0400" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="14.0" SD_2="34.78" SE="0.43151920606932676" STUDY_ID="STD-Safdi--2006" TOTAL_1="12" TOTAL_2="14" WEIGHT="45.33229369279061"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1436284458997127" CI_START="-1.4097796595626004" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6330756068314439" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2009-07-21 10:15:28 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.11014837194515878" Q="0.0" RANDOM="NO" SCALE="4.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="1.5975266055550685">
<NAME>Quality of life scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1436284458997127" CI_START="-1.4097796595626004" EFFECT_SIZE="-0.6330756068314439" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.1" MODIFIED="2009-05-20 05:18:39 -0400" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="1.08" SD_2="0.74" SE="0.3962848597513521" STUDY_ID="STD-Safdi--2006" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-05-25 10:06:21 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Different dosage schedules</NAME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-07-29 08:45:22 -0400" MODIFIED_BY="Jenny Bellorini" NO="3">
<NAME>Different enzymatic preparations</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6851027445305174" CI_START="-0.42489290184870654" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.13010492134090546" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2009-07-29 08:45:22 -0400" MODIFIED_BY="Jenny Bellorini" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6459017239278171" Q="0.0" RANDOM="NO" SCALE="1.627898996075201" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="99.99999999999999" Z="0.4594629913574845">
<NAME>Amount of faecal fat</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6851027445305174" CI_START="-0.42489290184870654" EFFECT_SIZE="0.13010492134090546" ESTIMABLE="YES" MEAN_1="10.68" MEAN_2="10.26" MODIFIED="2009-06-09 04:23:58 -0400" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="3.3" SD_2="3.05" SE="0.2831673579552298" STUDY_ID="STD-Delhaye--1996" TOTAL_1="25" TOTAL_2="25" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-08-10 11:12:30 -0400" MODIFIED_BY="Karin L Dearness">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-10 11:12:26 -0400" MODIFIED_BY="Karin L Dearness" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADOCAMAAAAdQhu+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-08-10 11:12:30 -0400" MODIFIED_BY="Karin L Dearness" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATQAAAIWCAIAAABWb+ZoAAAYmklEQVR42u3dvW4kxxWG4QGcOGDA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-12-16 15:55:29 -0500" MODIFIED_BY="Karin L Dearness">
<APPENDIX ID="APP-01" MODIFIED="2008-12-16 15:55:29 -0500" MODIFIED_BY="Karin L Dearness" NO="1">
<TITLE MODIFIED="2008-12-12 16:00:14 -0500" MODIFIED_BY="Karin L Dearness">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-12-12 16:00:16 -0500" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;Please provide the details of the entire search.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-12-12 16:00:16 -0500" NOTES_MODIFIED_BY="Karin L Dearness">
<P>exp pancreatitis/<BR/>(chronic adj3 pancreatitis).tw.<BR/>or/30-31<BR/>(pancreatic adj2 enzyme$).tw.<BR/>32 and 33<BR/>29 and 34</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>